Michael Tadros, MD, MPH, discusses how lessons learned from HCV treatment could improve the management of metabolic ...

A new study offers hope for earlier detection for fatty liver disease. This new blood test claims to predict it 16 years ...

The future of treating metabolic dysfunction–associated steatohepatitis (MASH) looks brighter than ever, says Naim Alkhouri, MD, as data emerges on newly developed interventions.

Research in Mayo Clinic's Liver Disease Immunobiology Lab led by Petra Hirsova, Pharm.D., Ph.D., focuses on metabolic dysfunction-associated steatohepatitis.

Doer Biologics begins patient dosing in phase 2 study of DR10624 to treat metabolic dysfunction-associated steatotic liver disease and MASH: Hangzhou, China Thursday, April 24, 20 ...

Injections of steroids and local anesthetics (nerve blocks) can provide long-lasting relief. Physical therapy, including ...

Many novel drugs are more relevant for subspecialists, but of the six first-in-class medications approved by the US Food and ...

A recent review highlights the gaps in clinical guidelines and treatment approaches for metabolic dysfunction-associated ...

A new biotech is hitting the Boston scene with $50 million from Flagship Pioneering and a goal of preventing patients from ...

The biotech is using AI and a trove of health data to better understand why certain conditions progress and intervene ...

MASH is when the extra fat in the liver starts to cause damage. About 30% of adults worldwide have MASLD. Rates are increasing as rates of other chronic conditions go up. MASLD is linked with many ...